

APPENDIX TABLE A2. CHANGES IN CHARACTERISTICS OF PATIENTS INITIATING SGLT2i OVER TIME

	2013 (n = 6424)	2014 (n = 20,997)	2015 (n = 27,293)	2016 (n = 20,786)	P
Demographics					
Age (years), mean (SD)	54.9 (9.5)	55.0 (9.9)	57.1 (10.9)	57.6 (11.3)	<0.001
Age category (years), n (%)					<0.001
18–44	886 (13.8)	3065 (14.6)	3467 (12.7)	2672 (12.9)	
45–64	4740 (73.8)	14,941 (71.2)	17,234 (63.1)	12,387 (59.6)	
65–74	671 (10.4)	2468 (11.8)	5090 (18.6)	4451 (21.4)	
≥75	127 (2.0)	523 (2.5)	1502 (5.5)	1276 (6.1)	
Sex, n (%)					0.15
Female	2781 (43.3)	9381 (44.7)	12,130 (44.4)	9328 (44.9)	
Male	3643 (56.7)	11,616 (55.3)	15,163 (55.6)	11,458 (55.1)	
Race/ethnicity, n (%)					<0.001
White	4475 (69.7)	14,081 (67.1)	17,801 (65.2)	13,308 (64.0)	
Black	812 (12.6)	2495 (11.9)	3421 (12.5)	2537 (12.2)	
Hispanic	775 (12.1)	3037 (14.5)	4110 (15.1)	3332 (16.0)	
Asian	190 (3.0)	736 (3.5)	975 (3.6)	833 (4.0)	
Unknown	172 (2.7)	648 (3.1)	986 (3.6)	776 (3.7)	
Census region, n (%)					<0.001
Midwest	1367 (21.3)	5186 (24.7)	6703 (24.6)	4983 (24.0)	
Northeast	539 (8.4)	1856 (8.8)	3136 (11.5)	2253 (10.8)	
South	3806 (59.2)	11,530 (54.9)	14,507 (53.2)	11,145 (53.6)	
West	712 (11.1)	2416 (11.5)	2930 (10.7)	2391 (11.5)	
Other/unknown	0 (0.0)	9 (0.0)	17 (0.1)	14 (0.1)	
Health insurance, n (%)					<0.001
Commercial	5506 (85.7)	17,704 (84.3)	19,603 (71.8)	14,180 (68.2)	
Medicare Advantage	918 (14.3)	3293 (15.7)	7690 (28.2)	6606 (31.8)	
Diabetes type and complications					
Diabetes type, n (%)					<0.001
Type 1 diabetes	119 (1.9)	477 (2.3)	413 (1.5)	245 (1.2)	
Type 2 diabetes	6305 (98.1)	20,520 (97.7)	26,880 (98.5)	20,541 (98.8)	
Number of diabetes complications, n (%)					<0.001
0	2877 (44.8)	10,328 (49.2)	12,867 (47.1)	9939 (47.8)	
1	1989 (31.0)	6010 (28.6)	7639 (28.0)	5700 (27.4)	
2	970 (15.1)	2672 (12.7)	3816 (14.0)	2835 (13.6)	
3	354 (5.5)	1221 (5.8)	1827 (6.7)	1387 (6.7)	
≥4	234 (3.6)	766 (3.6)	1144 (4.2)	925 (4.5)	
Diabetes complications, n (%)					
Retinopathy	995 (15.5)	3102 (14.8)	3956 (14.5)	2748 (13.2)	<0.001
Nephropathy	840 (13.1)	2446 (11.6)	3538 (13.0)	2767 (13.3)	<0.001
Neuropathy	1530 (23.8)	4443 (21.2)	6458 (23.7)	4977 (23.9)	<0.001
Cerebrovascular disease	315 (4.9)	1012 (4.8)	1367 (5.0)	1122 (5.4)	0.05
Cardiovascular disease	1346 (21.0)	4115 (19.6)	5876 (21.5)	4676 (22.5)	<0.001
Peripheral vascular disease	465 (7.2)	1583 (7.5)	2269 (8.3)	2053 (9.9)	<0.001
Severe hyperglycemia	127 (2.0)	424 (2.0)	447 (1.6)	313 (1.5)	<0.001
Severe hypoglycemia	399 (6.2)	1216 (5.8)	1862 (6.8)	911 (4.4)	<0.001

(continued)

TABLE AT2. (CONTINUED)

	2013 (n = 6424)	2014 (n = 20,997)	2015 (n = 27,293)	2016 (n = 20,786)	P
Additional comorbidity burden					
Charlson index, mean (SD)	2.4 (1.8)	2.2 (1.7)	2.4 (1.8)	2.4 (1.9)	<0.001
Charlson index category, <i>n</i> (%)					<0.001
0–1	2957 (46.0)	10,317 (49.1)	12,670 (46.4)	9514 (45.8)	
2	863 (13.4)	2775 (13.2)	3592 (13.2)	2526 (12.2)	
3	1333 (20.8)	4188 (19.9)	5317 (19.5)	4165 (20.0)	
≥4	1271 (19.8)	3717 (17.7)	5714 (20.9)	4581 (22.0)	
Key comorbidities, <i>n</i> (%)					
Acute MI	137 (2.1)	473 (2.3)	660 (2.4)	539 (2.6)	0.06
Heart failure	400 (6.2)	993 (4.7)	1504 (5.5)	1228 (5.9)	<0.001
Cerebrovascular disease	354 (5.5)	1174 (5.6)	1612 (5.9)	1312 (6.3)	0.008
Chronic kidney disease	400 (6.2)	1174 (5.6)	1929 (7.1)	1564 (7.5)	<0.001
Hypertension	5334 (83.0)	16,880 (80.4)	21,763 (79.7)	16,343 (78.6)	<0.001
Cancer	375 (5.8)	970 (4.6)	1500 (5.5)	1111 (5.3)	<0.001
Treatment regimen					
Initiated drug, <i>n</i> (%)					<0.001
Canagliflozin	6424 (100.0)	14,571 (69.4)	18,799 (68.9)	13,032 (62.7)	
Dapagliflozin	0 (0.0)	6204 (29.5)	3988 (14.6)	1711 (8.2)	
Empagliflozin	0 (0.0)	222 (1.1)	4506 (16.5)	6043 (29.1)	
SGLT2i strategy, <i>n</i> (%)					<0.001
First-line monotherapy	240 (3.7)	749 (3.6)	1060 (3.9)	909 (4.4)	
First-line combination therapy	223 (3.5)	799 (3.8)	1594 (5.8)	1641 (7.9)	
Add-on	5676 (88.4)	18,521 (88.2)	23,484 (86.0)	17,341 (83.4)	
Replacement	285 (4.4)	928 (4.4)	1155 (4.2)	895 (4.3)	
Number of drugs at baseline, <i>n</i> (%)					<0.001
0	463 (7.2)	1548 (7.4)	2654 (9.7)	2550 (12.3)	
1	1535 (23.9)	5592 (26.6)	8160 (29.9)	6707 (32.3)	
2	2241 (34.9)	7504 (35.7)	9867 (36.2)	7529 (36.2)	
≥3	2185 (34.0)	6353 (30.3)	6612 (24.2)	4000 (19.2)	
Number of drugs after index drug initiation, <i>n</i> (%)					<0.001
1	525 (8.2)	1677 (8.0)	2215 (8.1)	1804 (8.7)	
2	1671 (26.0)	5963 (28.4)	8691 (31.8)	7201 (34.6)	
3	2297 (35.8)	7667 (36.5)	10,336 (37.9)	7776 (37.4)	
≥4	1931 (30.1)	5690 (27.1)	6051 (22.2)	4005 (19.3)	
Baseline insulin use, <i>n</i> (%)	3535 (55.0)	10,535 (50.2)	12,124 (44.4)	6567 (31.6)	<0.001
Prescribing specialty, <i>n</i> (%)					<0.001
Cardiology	19 (0.3)	84 (0.4)	130 (0.5)	120 (0.6)	
Endocrinology	>2169 (>33.8) ^a	5664 (27.0)	<5893 (<21.6) ^a	3933 (18.9)	
Family medicine	1826 (28.4)	6723 (32.0)	9049 (33.2)	6699 (32.2)	
Internal medicine	1546 (24.1)	5073 (24.2)	6707 (24.6)	5016 (24.1)	
Pediatrics	<11 (<0.2) ^a	26 (0.1)	>56 (>0.2) ^a	26 (0.1)	
Other/unknown	853 (13.3)	3427 (16.3)	5458 (20.0)	4992 (24.0)	

^aData with cells containing ≤11 patients are suppressed to maintain strict patient deidentification.
MI, myocardial infarction; SD, standard deviation.